Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
2019 · New England Journal of Medicine · 1,130 citations
https://doi.org/10.1056/nejmoa1900750
T
Tadakazu Hisamatsu
Toho University(JP)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
620
Papers
14.1K
Citations
60
h-index
183
i10-index
Tadakazu Hisamatsu is an academic researcher from Toho University. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Eosinophilic Esophagitis. The author has an h-index of 60, co-authored 527 publications.
ORCID: 0000-0002-1178-3536Papers by this author
worksRisankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
2022 · The Lancet · 369 citations
https://doi.org/10.1016/s0140-6736(22)00467-6
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
2022 · The Lancet · 299 citations
https://doi.org/10.1016/s0140-6736(22)00466-4
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
2022 · Gastroenterology · 188 citations
https://doi.org/10.1053/j.gastro.2022.01.047
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study
2018 · Journal of Gastroenterology · 123 citations
https://doi.org/10.1007/s00535-018-1486-7
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Gastroenterology · 88 citations
https://doi.org/10.1053/j.gastro.2023.08.038
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat